Physician profile
Nicolas Ajkay
NPI 1497928261
$11,189.34
in general payments reported to CMS, 2019-2025
21 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $95.91 · 2022: $10K · 2023: $197 · 2024: $61.39 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $9,927.94 | 2022 | |
| Amgen INC. | $226.88 | 2019-2020 | |
| Davol INC. | $164.85 | 2025 | Arista |
| Abbvie INC. | $163.30 | 2023 | Strattice Reconstructive Tissue Matrix Bps |
| Stryker Corporation | $148.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $96.61 | 2024-2025 | |
| Becton, Dickinson and Company | $69.46 | 2022 | |
| Merck Sharp & Dohme LLC | $60.11 | 2019-2023 | Keytruda, Lynparza |
| Foundation Medicine, INC. | $56.34 | 2019 | |
| Janssen Biotech, INC. | $51.62 | 2019 | |
| Allergan, INC. | $49.65 | 2019 | |
| Focal Therapeutics, INC. | $43.73 | 2019 | |
| Celgene Corporation | $29.04 | 2019 | |
| Vivus LLC | $17.39 | 2022 | |
| Eisai INC. | $15.03 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Accelerator Applications | $14.59 | 2020 | |
| Dilon Technologies, INC. | $14.40 | 2023 | Hemoblast Bellows |
| Genzyme Corporation | $14.08 | 2020 | |
| Stemline Therapeutics INC. | $13.99 | 2024 | Orserdu |
| Lilly USA, LLC | $11.48 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Ajkay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.